These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 29082265)

  • 1. Vaccinomics Approach for Designing Potential Peptide Vaccine by Targeting
    Oany AR; Pervin T; Mia M; Hossain M; Shahnaij M; Mahmud S; Kibria KMK
    J Immunol Res; 2017; 2017():6412353. PubMed ID: 29082265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In silico design of a vaccine candidate based on autotransporters and HSP against the causal agent of shigellosis, Shigella flexneri.
    León Y; Zapata L; Salas-Burgos A; Oñate A
    Mol Immunol; 2020 May; 121():47-58. PubMed ID: 32163758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoinformatic identification of the epitope-based vaccine candidates from Maltoporin, FepA and OmpW of Shigella Spp, with molecular docking confirmation.
    Ullah H; Mahmud S; Hossain MJ; Islam MSB; Kibria KMK
    Infect Genet Evol; 2021 Dec; 96():105129. PubMed ID: 34737105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Towards a peptide-based vaccine against Shigella sonnei: A subtractive reverse vaccinology based approach.
    Baseer S; Ahmad S; Ranaghan KE; Azam SS
    Biologicals; 2017 Nov; 50():87-99. PubMed ID: 28826780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Shigellosis.
    Niyogi SK
    J Microbiol; 2005 Apr; 43(2):133-43. PubMed ID: 15880088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of vaccine and drug targets in Shigella dysenteriae sd197 using reverse vaccinology approach.
    Jalal K; Abu-Izneid T; Khan K; Abbas M; Hayat A; Bawazeer S; Uddin R
    Sci Rep; 2022 Jan; 12(1):251. PubMed ID: 34997046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The sigA gene which is borne on the she pathogenicity island of Shigella flexneri 2a encodes an exported cytopathic protease involved in intestinal fluid accumulation.
    Al-Hasani K; Henderson IR; Sakellaris H; Rajakumar K; Grant T; Nataro JP; Robins-Browne R; Adler B
    Infect Immun; 2000 May; 68(5):2457-63. PubMed ID: 10768931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In silico analysis to identify vaccine candidates common to multiple serotypes of Shigella and evaluation of their immunogenicity.
    Pahil S; Taneja N; Ansari HR; Raghava GPS
    PLoS One; 2017; 12(8):e0180505. PubMed ID: 28767653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recognition of three epitopic regions on invasion plasmid antigen C by immune sera of rhesus monkeys infected with Shigella flexneri 2a.
    Turbyfill KR; Joseph SW; Oaks EV
    Infect Immun; 1995 Oct; 63(10):3927-35. PubMed ID: 7558301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies.
    Kotloff KL; Winickoff JP; Ivanoff B; Clemens JD; Swerdlow DL; Sansonetti PJ; Adak GK; Levine MM
    Bull World Health Organ; 1999; 77(8):651-66. PubMed ID: 10516787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of multivalent Shigella-ETEC candidate vaccine strains in a guinea pig model.
    Barry EM; Wang J; Wu T; Davis T; Levine MM
    Vaccine; 2006 May; 24(18):3727-34. PubMed ID: 16169130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Towards a vaccine candidate against Shigella dysenteriae 1: expression of the Shiga toxin B-subunit in an attenuated Shigella flexneri aroD carrier strain.
    Tzschaschel BD; Klee SR; de Lorenzo V; Timmis KN; Guzmán CA
    Microb Pathog; 1996 Oct; 21(4):277-88. PubMed ID: 8905616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Towards a non-living vaccine against Shigella flexneri: from the inactivation procedure to protection studies.
    Camacho AI; Souza-Rebouças J; Irache JM; Gamazo C
    Methods; 2013 May; 60(3):264-8. PubMed ID: 23046911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An attenuated Shigella mutant lacking the RNA-binding protein Hfq provides cross-protection against Shigella strains of broad serotype.
    Mitobe J; Sinha R; Mitra S; Nag D; Saito N; Shimuta K; Koizumi N; Koley H
    PLoS Negl Trop Dis; 2017 Jul; 11(7):e0005728. PubMed ID: 28727722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Shigella outer membrane protein PSSP-1 is broadly protective against Shigella infection.
    Kim JO; Rho S; Kim SH; Kim H; Song HJ; Kim EJ; Kim RY; Kim EH; Sinha A; Dey A; Yang JS; Song MK; Nandy RK; Czerkinsky C; Kim DW
    Clin Vaccine Immunol; 2015 Apr; 22(4):381-8. PubMed ID: 25651919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outer membrane protein A (OmpA) from Shigella flexneri 2a: a promising subunit vaccine candidate.
    Pore D; Chakrabarti MK
    Vaccine; 2013 Aug; 31(36):3644-50. PubMed ID: 23764536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent progress towards development of a Shigella vaccine.
    Camacho AI; Irache JM; Gamazo C
    Expert Rev Vaccines; 2013 Jan; 12(1):43-55. PubMed ID: 23256738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How Do the Virulence Factors of
    Mattock E; Blocker AJ
    Front Cell Infect Microbiol; 2017; 7():64. PubMed ID: 28393050
    [No Abstract]   [Full Text] [Related]  

  • 19. Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults.
    Cohen D; Ashkenazi S; Green MS; Gdalevich M; Robin G; Slepon R; Yavzori M; Orr N; Block C; Ashkenazi I; Shemer J; Taylor DN; Hale TL; Sadoff JC; Pavliakova D; Schneerson R; Robbins JB
    Lancet; 1997 Jan; 349(9046):155-9. PubMed ID: 9111538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serogroup distribution of Shigella in Ile-Ife, southwest Nigeria.
    Abdu A; Aboderin AO; Elusiyan JB; Kolawole DO; Lamikanra A
    Trop Gastroenterol; 2013; 34(3):164-9. PubMed ID: 24851526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.